The University of Chicago Header Logo

Connection

Mark Lingen to Genetic Therapy

Back to Details
This is a "connection" page, showing publications Mark Lingen has written about Genetic Therapy.
Mark Lingen
Connection Strength
0.020
Genetic Therapy
  1. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.